RetatrutideTier 1
Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors being developed for obesity and type 2 diabetes. Phase 2 randomized controlled trials reported among the largest weight reductions seen for an incretin-based therapy, and phase 3 trials are underway. It is not FDA-approved and is not available as a finished prescription product.